|Articles|June 4, 2012

MedPoint Digital Expands Mobile Services for Clinical Trials

MedPoint Digital, a digital services provider to the global biopharma industry, recently announced a new generation of eClinical technologies for mobile devices. The new mobile-friendly platforms deployed by MedPoint include:

TriPort Clinical Trial Portal—MedPoint has evolved its core clinical portal to span the worlds of desktop and mobile, so it is compatible across devices, operating systems and browsers. TriPort is a secure, fully validated clinical trial technology that delivers study-specific information, training, and communications. TriPort is built for interoperability and supports role-based access to study resources and individual tracking of activity completion.

TelePoint Virtual Meeting System—The latest TelePoint release is cross-platform compatible, supporting live virtual meetings that simultaneously connect participants from desktop computers, smart phones, and tablets. This proprietary system works across all major operating systems and devices, blurring the lines between conventional web conferencing and app-enabled conferencing.

ActivMedia Modules—MedPoint has implemented a new mobile-compatible development platform to produce its next generation of multimedia/interactive web modules. Using its ActivMedia platform, MedPoint develops intuitive web modules that engage users for self-learning, real-world simulations, and training certification.

SFX Site Feasibility Xelerator—With the latest release of the SFX platform, study sites can complete survey forms over their mobile devices, making it faster and easier for sponsors to collect site profile information into a secure workspace for analysis, vetting, and promotion.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

October 2nd, 2026

What ClinOps Professionals Just Starting With AI Should Keep Top of Mind

In this video interview, Claire Riches, VP of clinical solutions at Citeline, offers practical guidance for clinical operations teams beginning their AI journey—making the case that the tools are more accessible than many assume and that waiting to start is a competitive risk in itself.

October 2nd, 2026

ACT Brief: Proactive Trial Risk Management, Federal Infrastructure Modernization, Pediatric Heart Disease Treatment

In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.

© Tada Images - © Tada Images - stock.adobe.com

October 1st, 2026

HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure

The new effort combines adaptive platform trial design, AI-enabled site activation, nationwide data infrastructure, and patient data contribution tools to reduce timelines, costs, and patient burden across clinical development.

October 1st, 2026

What an AI-Informed Approach Means for How Sponsors Think About Risk

In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is shifting trial risk management from reactive to proactive—enabling sponsors to pressure-test protocols and anticipate pivots before a single patient is enrolled.

October 1st, 2026

ACT Brief: AI as Design Advisor, Autonomous Agent Governance, Oral Weight-Loss Therapy Switch

In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.

September 30th, 2026

The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials

AI agents in clinical operations acquire broader autonomous capability through expanded permissions, tools, memory, and delegated authority, requiring governance focused on whether effective capability has shifted outside approved boundaries rather than whether software has changed.

September 30th, 2026

Where AI Leads in Trial Design—and Where Humans Still Need To

In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.

September 30th, 2026

ACT Brief: Enrollment Feasibility Pressure-Testing, RWE Infrastructure Gaps, and Peptide Rulemaking Standstill

In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.